JP2023521361A - コロナウイルス科感染の治療において使用するためのアプタマー - Google Patents

コロナウイルス科感染の治療において使用するためのアプタマー Download PDF

Info

Publication number
JP2023521361A
JP2023521361A JP2022561426A JP2022561426A JP2023521361A JP 2023521361 A JP2023521361 A JP 2023521361A JP 2022561426 A JP2022561426 A JP 2022561426A JP 2022561426 A JP2022561426 A JP 2022561426A JP 2023521361 A JP2023521361 A JP 2023521361A
Authority
JP
Japan
Prior art keywords
aptamer
receptor
seq
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521361A5 (https=
Inventor
アンネカトリン ハーバーラント
ヨハネス ミュラー
ゲルト ウォルカット
ペーター グッテル
Original Assignee
ベルリン キュアーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルリン キュアーズ ゲーエムベーハー filed Critical ベルリン キュアーズ ゲーエムベーハー
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Publication of JP2023521361A publication Critical patent/JP2023521361A/ja
Publication of JP2023521361A5 publication Critical patent/JP2023521361A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022561426A 2020-04-09 2021-04-09 コロナウイルス科感染の治療において使用するためのアプタマー Pending JP2023521361A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20168929.6 2020-04-09
EP20176023 2020-05-22
EP20176023.8 2020-05-22
EP20180781.5 2020-06-18
EP20180781 2020-06-18
EP20204036 2020-10-27
EP20204036.6 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (2)

Publication Number Publication Date
JP2023521361A true JP2023521361A (ja) 2023-05-24
JP2023521361A5 JP2023521361A5 (https=) 2024-08-02

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561426A Pending JP2023521361A (ja) 2020-04-09 2021-04-09 コロナウイルス科感染の治療において使用するためのアプタマー

Country Status (11)

Country Link
US (1) US12606828B2 (https=)
EP (1) EP4133083A1 (https=)
JP (1) JP2023521361A (https=)
KR (1) KR20220166337A (https=)
CN (1) CN115768895A (https=)
AU (1) AU2021252151A1 (https=)
BR (1) BR112022020439A2 (https=)
CA (1) CA3175067A1 (https=)
IL (1) IL297155A (https=)
MX (1) MX2022012618A (https=)
ZA (1) ZA202212179B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509645A (ja) * 2021-04-09 2024-03-04 ベルリン キュアーズ ゲーエムベーハー コロナウイルス科感染の治療において使用するためのアプタマー

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 ＳＡＲＳＣｏＶ２의 외피 단백질에 특이적으로 결합하는 ＤＮＡ 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP0208A (xx) * 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
CN117653654A (zh) * 2016-11-23 2024-03-08 柏林制药股份有限公司 用于抑制和/或压制tlr9激活的适体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMBIOCHEM, vol. 9, JPN6025013711, 2008, pages 3037 - 3045, ISSN: 0005692704 *
CHEMRXIV(TM), JPN6025013712, 4 April 2020 (2020-04-04), ISSN: 0005692705 *
新型コロナウイルスに対するラクダ科動物由来のVHH抗体 SARS-COV-2 SPIKE RBD LLAMABODY VHH DOMAIN ANTIBO, JPN6025013710, 16 May 2022 (2022-05-16), ISSN: 0005692703 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509645A (ja) * 2021-04-09 2024-03-04 ベルリン キュアーズ ゲーエムベーハー コロナウイルス科感染の治療において使用するためのアプタマー

Also Published As

Publication number Publication date
US20230140490A1 (en) 2023-05-04
ZA202212179B (en) 2025-03-26
KR20220166337A (ko) 2022-12-16
CA3175067A1 (en) 2021-10-14
US12606828B2 (en) 2026-04-21
EP4133083A1 (en) 2023-02-15
IL297155A (en) 2022-12-01
AU2021252151A1 (en) 2022-12-08
CN115768895A (zh) 2023-03-07
BR112022020439A2 (pt) 2022-11-29
MX2022012618A (es) 2022-11-07

Similar Documents

Publication Publication Date Title
US11466081B2 (en) Oligonucleotides for reduction of PD-L1 expression
JP7267689B2 (ja) 自己抗体関連疾患に対する使用のためのアプタマー
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
US12606828B2 (en) Aptamers for use in the treatment of Coronaviridae infections
JP2026021387A (ja) コロナウイルス科感染の治療において使用するためのアプタマー
WO2021205012A1 (en) Aptamers for use in the treatment of coronaviridae infections
EP4605008A1 (en) Alpha-v beta-6 integrin ligands for extrahepatic delivery
JP6368363B2 (ja) デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物
HK40104624A (en) Aptamers for use in the treatment of coronaviridae infections
HK40104624B (en) Aptamers for use in the treatment of coronaviridae infections
WO2024017951A1 (en) Modulation of a lncrna in the treatment of hiv

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221129

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221214

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260428